Synta’s Ganetespib Could Break The Hsp90i Curse

If ganetespib succeeds in Phase III, it could become the first new treatment for advanced lung adenocarcinoma in a decade, but the heat shock protein class has yet to produce a winner.

CHICAGO – Synta Pharmaceuticals Corp.’s second-generation heat shock protein 90 (Hsp 90) inhibitor ganetespib may provide the first successful proof of principle for the class and the first drug in a decade to improve outcomes in the salvage setting for advanced lung cancer.

Top-line results for the Phase II GALAXY-I trial in patients with stage IV adenocarcinoma of the lung were reported at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D